Envisagenics is a biotechnology company using artificial intelligence and RNA sequencing to discover and develop therapeutics that arrest RNA splicing errors in cancer and genetic diseases. The company is headquartered in New York City, New York and was founded in 2014 by Maria Luisa Pineda and Martin Akerman.
Envisagenics looks to provide means to reduce biomedical data in order to accelerate the creation of new therapeutic solutions. They are focused on finding solutions that help accommodate people who are affected by genetic diseases or cancer, especially if caused by mutations that affect RNA splicing.
Their technologies are designed to accelerate target identification for RNA splicing error discovery, as well as RNA therapeutic design and validation which they perform on their dedicated artificial intelligence discovery platform, and to increase the value of RNA sequencing data.
On November 23, 2017 Envisgenics closed their seed funding round with $2.35 million in funding. Dynamk Capital lead the seed funding round, but several other investors participated, including: Third Kind Venture Capital, SV Angel, New York State, Dolby Family Ventures, and Cosine.
Timeline
Funding rounds
People
Adam Geier
Employee
Adrian Krainer
Professor & Program Chair
Anson Abraham
Employee
Derrick Stroman
Employee
Gillian Sandler
Investor
Maria Luisa Pineda
Founder
Maria Luisa Pineda
Co-Founder & CEO
Martin Akerman
Founder
Martin Akerman
Co-Founder & CTO
Michael Schatz
Associate Research Professor
Michael Zhang
Professor & Director
Omar Abdel-Wahab
Hematologic Oncologist
Tiffany Tsui
Employee
Further reading
Microsoft Announces Winners of AI Startup Competition
Meir Orbach
Web
Platform Targeting Genetic Cause of SMA and Like Diseases Supported by $1.5M NIH Grant
Carolina Henriques
Web
Thiel's Breakout Labs backs Envisagenics
Gina Hall
Web